Join to access to all OVN content. Join for Free
The Role of MSLs in Achieving Health Equity
health equity healthcare inequity pharmaceutical companies patient advocacy FDA regulations

The Role of MSLs in Achieving Health Equity


Share This Article


Summary

In this episode, Ariel Katz, co-founder of H1, joins Tom Caravela to discuss the crucial topic of health equity. Ariel shares insights into his background and the mission of H1, defining health equity and exploring the causes of healthcare inequity. The conversation delves into the roles of MSLs and leadership in promoting health equity and highlights the actions pharmaceutical companies can take, emphasizing patient advocacy. The discussion also covers the impact of stricter FDA regulations on future MSL engagement and the importance of engaging with low and middle-income communities. Ariel offers final thoughts on raising awareness and building trust in healthcare.

My guest today is Ariel Katz, CEO and Founder of H1 and we discuss the role of MSLs in achieving Health Equity.

This episode is sponsored by H1, for info please visit www.H1.co

Ariel shares…

👉 His definition of health equity and why it has become a problem
👉 How MSLs fit into the equation for health equity and what can they do
👉 What pharma and biotech companies can do to assist in this effort to achieve health equity
👉 What patients need to be aware of and what can they do to help themselves
👉 The role of the FDA and what regulators can and should be doing

Click for Source
health equity, healthcare inequity, pharmaceutical companies, patient advocacy, FDA regulations

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Patient involvement: A must-have in medicine development, but is it being overlooked in a cost-constrained environment?
Partner Avatar Envision Pharma Group

Patient involvement: A must-have in medicine development, but is it being overlooked in a cost-constrained environment?

Press Release
Breaking Silos in Oncology Dr Ramin Farhood & Dr Kirk Shepard on Voices of Oncology
OVN Avatar Joe Pardavila sits down with Dr. Ramin Farhood and Dr. Kirk Shepard

Breaking Silos in Oncology Dr Ramin Farhood & Dr Kirk Shepard on Voices of Oncology

Article
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis
OVN Avatar Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis

Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis

Article
Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
OVN Avatar Avi Cherla, MSc; Huseyin Naci, MHS, PhD; Aaron S. Kesselheim, MD, JD, MPH; Bishal Gyawali, MD, PhD; Elias Mossialos, MD, PhD

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval

Article
Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review
OVN Avatar Vanessa Arciero, BS, Seanthel Delos Santos, Liza Koshy

Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review

Article
Clinical Educator Oncology Program Improves Adherence by 29%​
Partner Avatar iNIZIO

Clinical Educator Oncology Program Improves Adherence by 29%​

Explore OVN